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Abstract 1 
Quantitative structure activity type models were developed in an attempt to predict the key features of peptide se-2 
quences having dipeptidyl peptidase IV (DPP-IV) inhibitory activity. The models were then employed to help pre-3 
dict the potential of peptides, which are currently reported in the literature to be present in the intestinal tract of hu-4 
mans following milk/dairy product ingestion, to act as inhibitors of DPP-IV. Two models (z- and v-scale) for short 5 
(2-5 amino acid residues) bovine milk peptides, behaving as competitive inhibitors of DPP-IV, were developed. The 6 
z- and the v-scale models (p < 0.05, R
2
 of 0.829 and 0.815, respectively) were then applied to 56 milk protein-7 
derived peptides previously reported in the literature to be found in the intestinal tract of humans which possessed a 8 
structural feature of DPP-IV inhibitory peptides (P at the N2 position). Ten of these peptides were synthetized and 9 
tested for their in vitro DPP-IV inhibitory properties. There was no agreement between the predicted and experimen-10 
tally determined DPP-IV half maximal inhibitory concentrations (IC50). However, the ranking for DPP-IV inhibitory 11 
potency of the competitive peptide inhibitors was conserved. Furthermore, potent in vitro DPP-IV inhibitory activity 12 
was observed with two peptides, LPVPQ (IC50 = 43.8  8.8 µM) and IPM (IC50 = 69.5  8.7 µM). Peptides present 13 
within the gastrointestinal tract of human may have promise for the development of natural DPP-IV inhibitors for 14 
the management of serum glucose. 15 
 16 
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1 Introduction 19 
Milk proteins contain specific peptide motifs, termed bioactive peptides (BAPs), which have 20 
been identified in vitro for their potential role in beneficially modulating specific biomarkers of 21 
health. To date, several dietary intervention studies have been conducted to investigate the effect 22 
of milk protein-derived peptides in human health [3, 7, 16]. While some studies have demon-23 
strated a positive role of milk protein-derived BAPs in humans, other studies have failed to iden-24 
tify an improvement in specific health biomarkers following the consumption of BAPs or intact 25 
milk proteins [31, 32]. 26 
The rate of discovery of peptide sequences originating from dietary proteins which display in 27 
vitro bioactive properties has increased over the past number of years. This has been made possi-28 
ble notably with advances in chromatographic separation techniques coupled with mass spectro-29 
metric detection of peptides [36]. In addition, quantitative structure activity relationship (QSAR) 30 
studies have allowed the development of a more in-depth understanding of BAP sequences [11, 31 
13, 34, 39]. QSAR generally consists in the analysis of multivariate peptide descriptors which 32 
are linked to biological activity using computational methods such as partial least square regres-33 
sion (PLSR), multiple linear regression (MLR), principal component analysis (PCA) or artificial 34 
neural networks (ANN) [10, 11]. QSAR has been applied in the study of angiotensin converting 35 
enzyme (ACE) inhibitory [14, 38, 52, 53], antimicrobial [5, 24, 40, 43], antioxidant [19, 20, 45] 36 
and bitter [15, 19, 37, 51] peptides. 37 
The main advantage of using QSAR approaches over qualitative assessment of peptides to study 38 
their bioactive properties is that QSAR may provide a means to predict the potency of specific 39 
peptide sequences. While several bioactive properties have been studied using QSAR, others do 40 
not appear, to date, to have been assessed with this approach. As already indicated, QSAR has 41 
been applied to different BAPs, however, to date, it does not appear to have been applied to di-42 
peptidyl peptidase IV (DPP-IV) inhibitory sequences. DPP-IV is an amino dipeptidyl peptidase 43 
which hydrolyses and inactivates the incretin hormones glucose dependent insulinotropic poly-44 
peptide (GIP), glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). Inhibition of DPP-IV 45 
can prevent incretin degradation, allowing maintenance of their insulinotropic activity during the 46 
post-prandial phase [6]. While DPP-IV inhibitory drugs (i.e., gliptins) are currently used for the 47 
treatment of type 2 diabetes (T2D), there is also a growing interest in employing naturally de-48 
rived compounds such as dietary peptides for their DPP-IV inhibitory properties [12, 33]. In this 49 
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context, several studies have shown that milk protein-derived peptides can inhibit DPP-IV in 50 
vitro [17, 25, 42, 47]. 51 
The antidiabetic properties of intact and hydrolyzed milk proteins has been reported in the litera-52 
ture [31, 32]. Numerous milk protein-derived peptides have been identified in the intestinal tract 53 
of humans following the ingestion of milk and dairy products [1, 2, 34]. However, the contribu-54 
tion of these peptides to human health is still unknown [32]. In vivo studies demonstrating the 55 
antidiabetic effect of milk protein-derived DPP-IV inhibitory peptides have been conducted in 56 
small animals [48, 49]. To our knowledge, no studies to date have reported that milk protein-57 
derived peptides present within the intestinal tract of humans could act as DPP-IV inhibitors. 58 
Therefore, the aim of this study was to demonstrate that peptides which may be released during 59 
the digestion of milk proteins in humans could inhibit DPP-IV. This was achieved by compiling 60 
a database of previously identified milk protein-derived peptides in the intestinal tract of humans 61 
following the ingestion of milk and dairy products. To facilitate the evaluation of these peptide 62 
sequences, a selection of 10 synthetic peptides was assessed for their in vitro DPP-IV inhibitory 63 
properties within this study. Therefore, a combination of knowledge of the structural features of 64 
DPP-IV inhibitory peptides (i.e., P at the N2 position) and a QSAR approach was used to predict 65 
the DPP-IV inhibitory potential of  > 250 peptides identified in the intestine of humans. 66 
2 Materials and methods 67 
2.1 Reagents 68 
Tris(hydroxymethyl)aminomethane (TRIS), trifluoroacetic acid (TFA), GP-p-nitroanilide (pNA), 69 
diprotin A (IPI) and porcine DPP-IV (≥ 10 units mg-1 protein) were obtained from Sigma Aldrich 70 
(Dublin, Ireland). Hydrochloric acid (HCl) was from VWR (Dublin, Ireland). The synthetic pep-71 
tides (purity  95 % (w/w)) employed to build the QSAR model, i.e., FP, HP, RP, VP, IPM, LPP, 72 
IPPL and IPSK, were obtained from Thermo Fisher Scientific (Ulm, Germany) while VPGEIVE, 73 
YPFPGP, LPQNIPPLT, IPPLTQT, TPVVVPP, YPVEPF, LPLPLL, QPHQPLPPT, QPLPPT, 74 
LPVPQ were from Genscript (Piscataway, NJ, USA). 75 
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2.2 DPP-IV inhibition assay and mode of inhibition 76 
The DPP-IV inhibition assay was conducted as described by Nongonierma and FitzGerald [25]. 77 
The peptides were tested in the concentration range of 12.5 × 10
-3
 to 1.25 mg mL
-1
 (final concen-78 
tration). Each sample was analyzed in triplicate (n=3). The DPP-IV half maximal inhibitory con-79 
centrations (IC50) were determined by plotting the percentage inhibition as a function of the con-80 
centration of test compound using a logistic regression. 81 
The mode of DPP-IV inhibition was assessed using the Lineweaver and Burk double reciprocal 82 
representation as previously described by Nongonierma and FitzGerald [25]. The peptides were 83 
evaluated at two concentrations, i.e., their IC50 values divided by 8 and 40. The concentrations of 84 
GP-pNA ranged from 0.1 to 0.5 mM (final concentration). These substrate concentrations were 85 
selected as they were consistent with the limits of detection for pNA and allowed the obtention 86 
of a linear response for the Lineweaver and Burk double reciprocal analysis 87 
2.3 QSAR of DPP-IV inhibitory peptides 88 
The QSAR model was developed as a tool to predict the DPP-IV inhibitory potency of unknown 89 
peptides, i.e., peptides specifically reported to be present in the intestinal tract following inges-90 
tion of milk/dairy products. All IC50 values were obtained with the same assay as previously de-91 
scribed for the determination of DPP-IV inhibition [25]. The peptides used to build the QSAR 92 
model consisted of competitive DPP-IV inhibitors which had been identified in previous studies 93 
(Table 1). Eight additional peptides present within milk proteins were tested for their in vitro 94 
DPP-IV inhibitory potential and included in the training set. Five of which (FP, HP, RP, VP and 95 
LPP) were predicted in silico to be of relevance to DPP-IV inhibition [26]. The z-scale (z1 (hy-96 
drophilicity), z2 (size) and z3 (charge)) from Hellberg, Sjoestroem, Skagerberg and Wold [9] and 97 
the structural v-scale (v1 (van der Waals volume), v2 (net charge index) and v3 (hydrophobic pa-98 
rameter of side chains)) developed by Lin, Long, Bo, Wang and Wu [21] were used for the ami-99 
no acid descriptors. The short peptide sequences incorporated in the QSAR model ranged from 2 100 
to 5 amino acid residues. Therefore, the peptide descriptors were generated using a method al-101 
lowing data treatment for peptides with various lengths as described by Li and Li [19]. The two 102 
N- and C-terminal amino acids of the peptides were used to generate the peptide descriptors. A 103 
PLSR was used to link the DPP-IV IC50 values to the peptide descriptors as outlined in Equation 104 
1: 105 
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 107 
With Y, the DPP-IV IC50 value; i: the N- or C- terminal position of the amino acid (1 or 2); j: the 108 
amino acid descriptor number (varying between 1 and 3);  and β: the coefficients of the model; 109 
c, and ε the constant and residual of the model, respectively. 110 
Generation of the peptide descriptors and the PLSR were carried out using Matlab (version 111 
R2014b, MathWorks, Inc, Natick, MA, USA). The training set for the model included 21 pep-112 
tides, while 5 peptides (test set) were randomly chosen (100 times) by the Matlab algorithm for 113 
cross-validation. 114 
2.4 Utilization of the QSAR model to predict the DPP-IV inhibitory potency of milk pro-115 
tein-derived peptides previously identified in the intestinal tract of humans 116 
A database consisting of > 250 peptides reported to be released during the digestion of milk pro-117 
teins in the intestinal tract of humans [1, 2, 4, 18, 22, 44] was compiled. Five peptides 118 
(YPFPGPIPN, FPGPIPN, LPQNIPPL, IPPLTQTPV and LPLPL) identified in the intestinal tract 119 
of humans have previously been reported as DPP-IV inhibitors in vitro (Supplementary Table 120 
S1). Out of the > 250 peptides, 56 possessed the DPP-IV inhibitory feature consisting of a P at 121 
position N2. Predicted DPP-IV IC50 values of these 56 peptides were calculated using the QSAR 122 
models (Equation 1). From these 56 peptides, 10 sequences (VPGEIVE, YPFPGP, LPQNIPPLT, 123 
IPPLTQT, TPVVVPP, YPVEPF, LPLPLL, QPHQPLPPT, QPLPPT, LPVPQ) having different 124 
predicted DPP-IV IC50 values and sharing common sequences with previously identified DPP-IV 125 
inhibitory peptides [28] were selected for further in vitro studies. At the time of the study, these 126 
10 sequences had not previously been reported for their DPP-IV inhibitory activity. The ten pep-127 
tides were synthetized and evaluated in vitro for their DPP-IV inhibitory properties. 128 
2.5 Statistical analysis 129 
The statistical analysis consisted of means comparison carried out with a one way ANOVA fol-130 
lowed by a Student Newman-Keuls test using SPSS (version 22, SPSS Inc., Chicago, IL, USA) 131 
at a significance level p < 0.05. For the QSAR models, the R
2
 and R
2
 cross validation were used 132 
to assess the significance of the PLSR. 133 
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3 Results 134 
3.1 DPP-IV inhibitory properties and mode of DPP-IV inhibition of peptides included in 135 
the dataset 136 
The eight additional synthetic milk protein-derived peptides (FP, HP, RP, VP, IPM, LPP, IPPL 137 
and IPSK) included in the training set were assessed for their DPP-IV inhibitory properties and 138 
their mode of inhibition. Their IC50 values ranged between 69.5  8.7 and 902.8  93.8 µM for 139 
IPM and HP, respectively (Table 1). Of these peptides, one (IPPL, Figure 1A) was uncompeti-140 
tive, two (FP and HP, Figure 1B) were mixed-type, one (LPP, Figure 1C) was non-competitive 141 
and four (IPM, VP, IPSK and RP, Figure 1D) were competitive inhibitors of DPP-IV. 142 
When peptides not behaving as competitive DPP-IV inhibitors as well as other peptide DPP-IV 143 
IC50 data from the literature obtained using different assay conditions were included in the train-144 
ing set, no significant relationship (p > 0.05) between the peptide descriptors and their DPP-IV 145 
IC50 values was obtained (data not shown). The DPP-IV IC50 values of the peptides included in 146 
the dataset were therefore those obtained from our previous studies [25-27, 29] with the excep-147 
tion RP, VP, IPM and IPSK, whose DPP-IV IC50 values were determined in this study (Table 1). 148 
All the DPP-IV IC50 values used to build the QSAR model were obtained using the same exper-149 
imental conditions [25]. Furthermore, the peptides included in the QSAR dataset only consisted 150 
of the competitive DPP-IV inhibitory peptides (26) as outlined in Table 1. 151 
3.2 QSAR models 152 
The two QSAR models linking the DPP-IV IC50 value to the peptide descriptors were significant, 153 
having a p of 0.00279 and 0.00437 for the z- and v-scale models, respectively (Table 2). The R
2
 154 
and
 
R
2
 cross validation values were > 0.75 for both models, which was indicative of a relatively 155 
good correlation between the DPP-IV IC50 values and the peptide descriptors (Figure 2A and 156 
2B). 157 
The parameters of the PLSR for the two QSAR models developed with the two scales for amino 158 
acid descriptors are shown in Table 3. For the QSAR model developed with the z-scale, the two 159 
coefficients linked with the hydrophilicity of the N1 (1,1) and N2 (2,1) terminal amino acids 160 
were significant (p < 0.05). The positive value of these coefficients suggested that a reduced hy-161 
drophilicity for the two N terminal amino acids would decrease the DPP-IV IC50 value (i.e., in-162 
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crease the potency). In the case of the v-scale model, only the coefficient linked with the hydro-163 
phobicity of the N1 (1,3) terminal amino acid was significant (p < 0.05). It was negatively corre-164 
lated to the DPP-IV IC50 value, suggesting that hydrophobic amino acids located at the N-165 
terminus of the peptides would tend to decrease the DPP-IV IC50 value. While both QSAR mod-166 
els resulted in different outcomes, they both predicted that the hydrophobicity of the N-terminal 167 
amino acid plays a significant role in DPP-IV inhibitory potency. 168 
3.3 Confirmatory studies with peptides relevant to human health 169 
Within the milk peptides identified in the intestine of humans following the ingestion of milk 170 
proteins and dairy products, 56 possessed a feature characteristic to that of previously identified 171 
DPP-IV inhibitors (i.e., P at position 2 of the peptide) as outlined elsewhere [8, 28, 46]. These 172 
peptides originated from - and s1-casein ([1, 4], Supplementary Table S1). Within these pep-173 
tides, 5 had already been reported in the literature to display in vitro DPP-IV inhibitory proper-174 
ties [29, 49], having DPP-IV IC50 values ranging from 46 and 1300 µM for LPQNIPPL and 175 
IPPLTQTPV, respectively (Supplementary Table S1). 176 
The two QSAR models (Table 3) were used to predict the DPP-IV IC50 values of the 56 peptides 177 
(Table 4 and Supplementary Table S1). Ten (VPGEIVE, YPFPGP, LPQNIPPLT, IPPLTQT, 178 
TPVVVPP, YPVEPF, LPLPLL, QPHQPLPPT, QPLPPT, LPVPQ) of the peptides identified in 179 
humans [1] were selected for subsequent confirmatory studies. These peptides were selected on 180 
the basis that they had a P in position N2 and contained sequences similar to previously identified 181 
DPP-IV inhibitory peptides [28]. Their DPP-IV IC50 values, as predicted by the 2 QSAR models, 182 
together with their DPP-IV IC50 values determined in vitro along with their mode of inhibition 183 
are shown in Table 4. All ten peptides were able to inhibit DPP-IV in vitro, having IC50 values 184 
ranging from 43.8  8.8 to 1754.8  375.0 µM for LPVPQ and QPHQPLPPT, respectively. Five 185 
(VPGEIVE, LPQNIPPLT, LPLPLL, QPLPPT and LPVPQ) of the peptides evaluated were com-186 
petitive DPP-IV inhibitors (Table 4) while the other peptides were uncompetitive (IPPLTQT) or 187 
mixed-type inhibitors (YPFPGP, TPVVVPP, YPVEPF and QPHQPLPPT). 188 
The z-scale QSAR model had the tendency to underestimate the IC50 value of the competitive 189 
DPP-IV inhibitors, while the opposite was seen with the v-scale model. Generally, there was no 190 
agreement with the DPP-IV IC50 values predicted with the two QSAR models and the experi-191 
mentally determined IC50 values. This was seen in particular when negative IC50 values were 192 
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predicted by the z-scale model. While it is not possible to obtain negative IC50 values, these val-193 
ues were indicative of a low predicted IC50. In general, the ranking of the competitive peptides in 194 
terms of their DPP-IV inhibitory potency was in agreement in both QSAR models with the ex-195 
perimental values (Table 4). 196 
4 Discussion 197 
Within this study, QSAR was used as a tool to rank peptides released in the intestinal tract of 198 
humans in relation to their ability to inhibit DPP-IV. Interestingly, statistically significant models 199 
were only obtained when incorporating data for competitive DPP-IV inhibitory peptides and for 200 
inhibitory data obtained using similar experimental conditions. This may be linked to the fact 201 
that the conditions employed during the enzyme inhibitory assays affect the final outcomes ob-202 
tained [23]. Therefore, in order to avoid the potential bias associated with the experimental con-203 
ditions, it may be more appropriate in the future to build the model with inhibition constant (Ki) 204 
values for DPP-IV, which do not depend on the assay conditions employed. 205 
An earlier study based on molecular docking of peptides to the active site of DPP-IV showed that 206 
there was a trend (R
2
 = 0.4083) between the Vina score and the DPP-IV IC50 for competitive 207 
peptide inhibitors. However, no relationship was found with non-competitive peptide inhibitors 208 
of DPP-IV [35]. The importance of taking into account the mode of DPP-IV inhibition of the 209 
peptides has again been highlighted by the results obtained herein during QSAR modelling.  210 
The two QSAR models did not allow an accurate prediction of the DPP-IV IC50 value as they 211 
tended to either over- (v-scale) or underestimate (z-scale) this value. This may be related to the 212 
length ( 5 amino acids) as well as the limited number of peptides included in the training set. 213 
Larger peptides and/or other physicochemical parameters may need to be incorporated in the 214 
model. The z5 scale, as developed by Sandberg, Eriksson, Jonsson, Sjöström and Wold [41], 215 
which incorporates more physicochemical parameters than the z3 scale used herein, was also 216 
used (data not shown). While a better correlation between the predicted and experimentally de-217 
termined DPP-IV IC50 values was obtained (R
2
 = 0.952) with the z5 scale, the only coefficient of 218 
the QSAR model which was significant (p < 0.05) was that of the intercept. The ranking of the 219 
peptide DPP-IV inhibitory potency was the same when comparing predicted and experimental 220 
DPP-IV IC50 values (Table 4 and Supplementary Table S1). In addition, both models (z- and v-221 
scale) showed that peptides possessing an hydrophobic N terminal amino acid (i.e., W, I, F and 222 
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L) were predicted to be relatively potent inhibitors of DPP-IV, which is in agreement with earlier 223 
studies [28, 35, 46]. Inclusion of peptides possessing a wider range of N-terminal amino acids 224 
may be advisable in order to verify this hypothesis in future studies. 225 
Several DPP-IV inhibitory peptides with a W at the N-terminal position have been reported in 226 
previous studies. A peptide alignment strategy described in an earlier study [28] has been applied 227 
to DPP-IV inhibitory peptides with IC50 values < 200 µM taking into account more recent infor-228 
mation available in the scientific literature (data not shown). Following this sequence alignment, 229 
it was seen that an I residue in position N1 and a P in the N2 position of the peptides were fre-230 
quently observed. Overall, there is a good agreement between the prediction obtained with the 231 
two QSAR models developed herein and the peptide alignment approaches when applied to 232 
DPP-IV inhibitory peptides [28, 46]. 233 
Of the peptides used in the training set, a novel and relatively potent DPP-IV inhibitory peptide, 234 
IPM (lactoferrin - LF (f 127-129) or LF (f 469-471)), having an IC50 value of 69.5  8.7 µM has 235 
been reported herein. This peptide has similar structural features (i.e., a tripeptide possessing an 236 
IP- N-terminus) as previously identified DPP-IV inhibitory peptides, IPI and IPA, having IC50 237 
values of 3.2 [50] and 49 µM [47], respectively. In addition, another relatively potent DPP-IV 238 
inhibitory peptide, LPVPQ (-CN (f 171-175)) originally reported within the milk protein-239 
derived peptides identified in the jejunum of humans [1], having an IC50 value of 43.8  8.8 µM 240 
was reported herein. 241 
It has been suggested that the insulinotropic properties of milk proteins and milk protein hydrol-242 
ysates are mediated by an increase in branched chain amino acid (BCAA) and/or in peptide lev-243 
els in the serum [30, 32]. Other mechanisms, including DPP-IV inhibition induced by milk pep-244 
tides, may also be involved in vivo. Ten selected milk protein-derived peptides identified in the 245 
jejunum of humans [1] were shown herein to inhibit DPP-IV in vitro. Insulinotropic properties 246 
have been reported in small animals following the administration of milk protein-derived pep-247 
tides and hydrolysates with in vitro DPP-IV inhibitory properties [48, 49]. However, to our 248 
knowledge, the inhibition of DPP-IV mediated by milk protein-derived peptides has not to date 249 
been reported in humans. DPP-IV is present in the gastrointestinal tract, therefore, it is likely that 250 
the peptides herein may have an effect on the inhibition of DPP-IV in the gut. Additional human 251 
intervention studies are required to verify this assumption. 252 
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5 Conclusions 253 
The QSAR approach developed within this study has allowed the ranking of competitive pep-254 
tides for their potential DPP-IV inhibitory activity. The models were used as a tool to predict the 255 
DPP-IV inhibitory properties of peptides which have previously been identified in the intestinal 256 
tract of humans following the ingestion of milk/dairy products. The potent DPP-IV inhibitory 257 
peptides reported herein may be relevant to human health. It is likely that other peptides identi-258 
fied in the gastrointestinal tract of humans following milk/dairy products ingestion and which 259 
were not incorporated in this study may also have the ability to inhibit DPP-IV. While applica-260 
tions of QSAR models in the current context have their limitations (with respect to peptide data 261 
set, size and diversity), it is still evident that this approach has shown significant promise in the 262 
discovery of new DPP-IV inhibitory peptide sequences. The impact of the milk protein-derived 263 
peptides identified in the gut needs to be assessed in vivo in order to better understand their role 264 
as serum glucose regulating agents. 265 
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Table captions 
 
Table 1. Dipeptidyl peptidase IV (DPP-IV) half maximal inhibitory concentration (IC50) and 
mode of inhibition of milk protein-derived peptides (this information was used to build the quan-
titative structure activity relationship (QSAR) models). 
 
Table 2. Statistical significance of the partial least square regression (PLSR) analysis linking the 
half maximal inhibitory concentration (IC50) for dipeptidyl peptidase IV (DPP-IV) of the com-
petitive peptide inhibitors used to generate the quantitative structure activity relationship 
(QSAR) models. 
 
Table 3. Coefficients of the partial least square regression (PLSR) analysis used to generate the 
quantitative structure activity relationship (QSAR) models linking the half maximal inhibitory 
concentration (IC50) for dipeptidyl peptidase IV (DPP-IV) with the peptide descriptors. 
 
Table 4. -Casein derived peptide sequences which have previously been identified in the intes-
tinal tract of humans following the ingestion of milk proteins [1] together with their predicted 
and experimentally determined dipeptidyl peptidase IV (DPP-IV) half maximal inhibitory con-
centration (IC50). This table contains the data obtained with the ten peptides selected for the con-
firmatory study. 
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Table 1 
Peptide sequence
1
 Milk protein fragment
2
 DPP IV IC50 (µM)
3
 Mode of inhibition Peptide length Reference 
IPI -CN (f 26-28) 3.5 competitive 3 [29] 
IPIQY -CN (f 26-30) 35.2 competitive 5 [29] 
FLQP -CN (f 102-105) 65.3 competitive 4 [26] 
IPM LF (f 127-129), LF (f 469-471) 69.5  8.7 competitive 3 this study 
LPYPY -CN (f 56-60) 108.3 competitive 5 [29] 
HL diverse 143.2 competitive 2 [25] 
IP diverse 149.6 competitive 2 [29] 
VA diverse 168.2 competitive 2 [25] 
YPYY -CN (f 58-61) 194.4 competitive 4 [29] 
LPL -CN (f 150-152), -CN (f 152-154) 241.4 competitive 3 [29] 
YPY -CN (f 58-60) 243.7 competitive 3 [29] 
WY s1-CN (f 164-165), -Lg (f 19-20) 281.0 competitive 2 [27] 
LPLPL -CN (f 150-154) 325.0 competitive 5 [29] 
VP diverse 380.3  28.4 competitive 2 this study 
FL diverse 399.6 competitive 2 [25] 
IPSK LF (f 310-313) 406.8  50.4 competitive 4 this study 
IPPL -CN (f 89-92) 428.9  36.1 uncompetitive 4 this study 
LPP -CN (f 166-168), BSA (f 301-303) 563.3  50.4 non-competitive 3 this study 
VLGP -CN (f 212-215) 580.4 competitive 4 [26] 
RP diverse 657.2  38.4 competitive 2 this study 
YP diverse 658.1 competitive 2 [29] 
FP diverse 682.5  79.4 mixed 2 this study 
LP diverse 712.5 competitive 2 [29] 
AL diverse 882.1 competitive 2 [25] 
HP diverse 902.8  93.8 mixed 2 this study 
LW s1-CN (f 198-199) 993.4 competitive 2 [27] 
LQP -CN (f 103-105) 1181.1 competitive 3 [26] 
SL diverse 2517.1 competitive 2 [25] 
GL diverse 2615.0 competitive 2 [25] 
  18 
EK diverse 3216.8 competitive 2 [25] 
1
DPP-IV inhibitory peptide sequences abbreviated using the one letter amino acid code. Peptides are ordered by increasing IC50 value. 
The competitive peptide inhibitors were used to generate the quantitative structure activity relationship (QSAR) models. 
2
BSA: bovine serum albumin, CN: casein, -Lg: -lactoglobulin, LF: lactoferrin.  
3
All DPP-IV IC50 values listed were obtained using the same experimental protocol as described in Nongonierma and FitzGerald [25]. 
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Table 2 
Parameter z-scale
 
v-scale 
n 26 26 
R
2 
model 0.829 0.815 
p model 0.00279 0.00437 
Root mean square error 484 504 
F 5.27 4.78 
R
2 
cross validation 0.775 0.754 
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Table 3 
Amino acid 
descriptors 
Coefficient Model 
coefficient 
Standard 
error 
tStat p
1
 
z-scale [9] c 1073 196 5.48 0.0001 
 1,1 146 60 2.42 0.03 
 1,2 -359 208 -1.73 0.11 
 1,3 37 210 0.18 0.86 
 2,1 213 96 2.22 0.04 
 2,2 -247 434 -0.57 0.58 
 2,3 -233 138 -1.69 0.12 
 1,1 -4 64 -0.06 0.95 
 1,2 155 200 0.77 0.45 
 1,3 -41 115 -0.36 0.72 
 2,1 -178 107 -1.66 0.12 
 2,2 545 413 1.32 0.21 
 2,3 -129 132 -0.98 0.35 
v-scale [21] c 1341 489 2.74 0.02 
 1,1 -318 2455 -0.13 0.90 
 1,2 7053 4614 1.53 0.15 
 1,3 -369 131 -2.82 0.01 
 2,1 3527 1859 1.90 0.08 
 2,2 518 2353 0.22 0.83 
 2,3 -478 254 -1.88 0.08 
 1,1 -1636 2498 -0.65 0.52 
 1,2 -2414 3337 -0.72 0.48 
 1,3 56 144 0.38 0.71 
 2,1 -396 1642 -0.24 0.81 
 2,2 -694 2232 -0.31 0.76 
 2,3 73 260 0.28 0.78 
1
Coefficients with a p < 0.05 are significantly different from 0. 
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Table 4 
Peptide  
Sequence
1
 
-Casein 
fragment 
DPP IV IC50 (µM) Mode of DPP-IV 
inhibition
4
 
  Predicted1
2
 Predicted2
2
 Experimental
3
  
VPGEIVE 8-14 -109 844 224.5  66.3 c competitive 
YPFPGP 60-65 nd nd 749.2  122.3 f mixed-type 
LPQNIPPLT 70-78 -195 519 205.2  32.5 c competitive 
IPPLTQT 74-80 nd nd 465.1  73.7 e uncompetitive 
TPVVVPP 80-86 nd nd 1408.9  179.0 h mixed-type 
YPVEPF 114-119 nd nd 124.7  9.1 b mixed-type 
LPLPLL 135-140 6 556 371.5  60.6 d competitive 
QPHQPLPPT 146-154 nd nd 1754.8  375.0 i mixed-type 
QPLPPT 149-154 447 1198 1013.8  162.4 g competitive 
LPVPQ 171-175 -491 97 43.8  8.8 a competitive 
nd: not determined 
1
Peptide sequences abbreviated using the one letter amino acid code.  
2
DPP-IV IC50 value predicted with the QSAR model developed with the z-scale (predicted 1) and 
v-scale (predicted 2) amino acid descriptors as described in Table 3. The predicted values were 
only determined for the competitive DPP-IV inhibitory peptides. The IC50 of the positive control 
IPI was of 3.73  0.56 µM. 
3
Mean  SD (n=3). Figures with different letters are significantly different at p < 0.05. 
4
The mode of inhibition was determined with the Lineweaver and Burk double reciprocal repre-
sentation. 
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Figure captions 
 
Figure 1. Lineweaver and Burk double reciprocal plots for dipeptidyl peptidase IV (DPP-IV) 
inhibition with (A) IPPL (uncompetitive), (B) HP (mixed-type), (C) LPP (non-competitive) and 
(D) RP (competitive) evaluated at concentrations corresponding to their IC50 divided by 8 and 
40. Each point is the mean  SD (n=4). 
 
Figure 2. Quantitative structure activity relationship (QSAR) models generated with the compet-
itive dipeptidyl peptidase IV (DPP-IV) inhibitors described in Table 1, using the amino acid de-
scriptors developed by (A) Hellberg, Sjoestroem, Skagerberg and Wold [9]  (z-scale) and (B) 
Lin, Long, Bo, Wang and Wu [21] (v-scale).
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Supplementary Table S1. Peptide sequences possessing features of previously identified dipeptidyl peptidase IV (DPP-IV) inhibitors 
(i.e., with a P at the N2 position), which have been found in the intestinal tract of humans following the ingestion of milk proteins [1, 
4] together with their predicted DPP-IV half maximal inhibitory concentration (IC50). The sequences reported in this Table contain the 
additional 46 peptides, which were not listed in Table 4. 
Peptide  
Sequence
1
 
Parent 
protein
2
 
Fragment DPP IV IC50 (µM) 
   Predicted1
3
 Predicted2
3
 Experimental
4 
Reference
4
 
YPFPGPI β-CN 60-66 217 407   
YPFPGPIP β-CN 60-67 371 572   
YPFPGPIPN β-CN 60-68 -978 237 670 [49] 
FPGPIP β-CN 62-67 -883 271   
FPGPIPN β-CN 62-68 -2232 -63 260 [49] 
LPQNIPPL β-CN 70-77 156 274 46 [49] 
LPQNIPPLTQT β-CN 70-80 -32 428   
LPQNIPPLTQTPV β-CN 70-82 -888 271   
IPPLTQTPV β-CN 74-82 -693 8 1300 [49] 
IPPLTQTPVVVPPFLQPE β-CN 74-91 -285 -170   
IPPLTQTPVVVPPFLQPEV β-CN 74-92 -691 303   
PPLTQ β-CN 75-79 -496 2556   
PPLTQTPV β-CN 75-82 -1020 2139   
PPLTQTPVVVPPFLQPE β-CN 75-91 -613 1961   
PPLTQTPVVVPPFLQPEV β-CN 75-92 -1018 2434   
TPVVVPPF β-CN 80-87 1630 670   
TPVVVPPFLQP β-CN 80-90 527 743   
TPVVVPPFLQPE β-CN 80-91 -220 538   
TPVVVPPFLQPEV β-CN 80-92 -626 1012   
TPVVVPPFLQPEVM β-CN 80-93 79 1135   
VPPFLQPE β-CN 84-91 266 413   
VPPFLQPEV β-CN 84-92 -140 886   
PPFLQ β-CN 85-89 -773 2246   
PPFLQPE β-CN 85-91 -613 1961   
  26 
PPFLQPEV β-CN 85-92 -1018 2434   
PPFLQPEVM β-CN 85-93 -313 2557   
MPFPK β-CN 109-113 511 -112   
YPVEPFT β-CN 114-120 473 376   
YPVEPFTESQ β-CN 114-123 -458 930   
LPLPL β-CN 135-139 156 274 325 [29] 
QPHQPLPPTVMFPPQS β-CN 146-161 -958 1399   
QPHQPLPPTVMFPPQSV β-CN 146-162 -727 1963   
QPLPPTV β-CN 149-155 -267 1823   
QPLPPTVMFPPQ β-CN 149-160 2 1057   
EPVLGPV β-CN 195-201 -301 1149   
EPVLGPVRGPF β-CN 195-205 1956 1102   
EPVLGPVRGPFP β-CN 195-206 994 1021   
EPVLGPVRGPFPI β-CN 195-207 439 1184   
EPVLGPVRGPFPII β-CN 195-208 192 1549   
VPPFLQPEV β-CN 84-92 -140 886   
YPVEPF β-CN 114-119 1735 325   
FPEVFGKE αs1-CN 28-35 -1082 -70   
VPQLEIVPN αs1-CN 106-114 -596 456   
EPMIGV αs1-CN 133-138 -1200 1609   
YPFPGPI β-CN 60-66 217 407   
HPIKHQGLPQEV αs1-CN 4-15 -838 917   
1
Peptide sequences abbreviated using the one letter amino acid code. 
2
CN: casein. 
3
DPP-IV IC50 value predicted with the QSAR model developed with the z-scale (predicted 1) and v-scale (predicted 2) amino acid de-
scriptors as described in Table 3. 
4
Experimental DPP-IV IC50 values as reported in previous studies. 
